KEY TAKEAWAYS
- The trial aimed to evaluate the survival benefit of adjuvant chemoradiotherapy in PDAC pts after surgery.
- The study compared OS and DFS were compared between the 2 groups.
- The study found adjuvant treatment improved survival in pancreatic cancer pts after surgery. Still, more information is needed to determine who benefits most from radiotherapy and which therapy combination is best.
Adjuvant chemoradiotherapy may help pancreatic ductal adenocarcinoma (PDAC) patients(pts) live longer, but more research is needed to know for sure. Researchers aimed to evaluate the survival benefit of adjuvant chemoradiotherapy in PDAC pts after surgery.
The study included pts from Zhongshan Hospital, Fudan University in Shanghai, China, who underwent surgical treatment between June 2020 and December 2021. Those with certain conditions were excluded. They were divided into three groups based on their adjuvant treatment: C- (no chemotherapy), C+R- (chemotherapy only), and C+R+ (chemoradiotherapy). The study compared their overall survival (OS) and disease-free survival (DFS).
The study involved 216 pts whose median follow-up times ranged from 18 to 21.9 months. Significant differences were observed in both overall survival (OS) and disease-free survival (DFS) among the three groups (OS P-value = 0.0088; DFS P-value = 0.0037). The median OS (mOS) for C- and C+R- groups were 24.3 (95% CI, 18 – NA) and 29.5 (24.9 – NA) months, respectively. The C+R+ group did not reach a median OS (27.2 – NA). Median DFS (mDFS) for C-, C+R-, and C+R+ were 8.42 (5.72 – NA), 16.9 (13.91 – NA), and 19.66 (16.83 – NA) months, respectively.
The study found adjuvant treatment improved survival in pancreatic cancer pts after surgery. Still, more information is needed to determine who benefits most from radiotherapy and which therapy combination is best.
Source: https://ascopubs.org/doi/abs/10.1200/JCO.2023.41.16_suppl.e16308
Clinical Trial: https://www.clinicaltrials.gov/study/NCT04737551
Lili Wu, Xi Guo, Yaolin Xu, Dansong Wang, Wenchuan Wu, Tiantao Kuang, Xuefeng Xu, Liang Liu, Wenquan Wang, Shisuo Du, Yuhong Zhou, and Wenhui Lou. DOI: 10.1200/JCO.2023.41.16_suppl.e16308 Journal of Clinical Oncology 41, no. 16_suppl (June 01, 2023) e16308-e16308.
